Research programme: anti-CXCR4 monoclonal antibodies - Northwest BiotherapeuticsAlternative Names: Antibodies to CXCR4 - Northwest Biotherapeutics
Latest Information Update: 04 Aug 2010
At a glance
- Originator Northwest Biotherapeutics
- Class Monoclonal antibodies
- Mechanism of Action CXCR4 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer